Eli Lilly says FDA broadens indication for Verzenio

Eli Lilly announced that the U.S. Food and Drug Administration approved an expanded indication for Verzenio, in combination with endocrine therapy, for the adjuvant treatment of adult patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive, early breast cancer at a high risk of recurrence. High risk patients eligible for Verzenio can now be identified solely based on nodal status, tumor size, and tumor grade. This expanded adjuvant indication removes the Ki-67 score requirement for patient selection, the company stated.